Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Sold out too, gla.
I'll have to change my name to BittenThriceShy....
It does say that "If the full $100 million is not returned, then the Company intends to return any remainder following the completion of the Tender Offer, by way of a special dividend."
If the price exceeds 250p by the time of the tender, no-one will sell and the whole lot will be returned as a special dividend.
Hopefully a special dividend, that should light a rocket under the share price, maybe....
More share buybacks would be a disappointment.
Yes, it's almost as if the market is saying "OK, you've taken two products to market and generated oodles of cash, but we don't believe that KarXT will get FDA approval, and we don't believe that any of the other 28 candidates will either."
I know where I sit on this, it's now my biggest holding too.
.....& 45,500 no votes from me.
8.6% according to the lse summary.
That's a pretty chunky payout whilst waiting for the share price to adjust to more realistic levels.
Could be worse - they could be sat in the middle of £3 million worth of apples.....
The presentation this morning was very informative and positive. The company is resisting the pressure to start share buybacks to bolster the pitifully low share price. I see this as positive, in that the company has far more productive ways of deploying capital. The development of MSALABS in North America is encouraging too, as it will help rid the company of the "Africa only" label, with all the unjustified risk premium that seems to attract.
There was a full page article on Eurobox in this week's Moneyweek. According to the article, there is no major debt refinancing until 2025. The article didn't specify the current interest rate but it's probably very low. What is interesting is that, unlike the UK, rental rates in the EU are index linked. Also, online sales in the UK are pretty mature whereas the EU has a lot of catching up to do, so more growth is expected there.
The share's pulled back as you expected/feared. The portfolio is still very high quality and the price should recover once interest rates start to fall. At the moment, nearly 8% dividend seems to be not enough risk premium for the market when interest rates are 5+%.
This has got to be THE most successful investment trust on the market today, yet there's literally zero interest in it on the message boards. Perhaps it should change its name to Literacy AI Blockchain Capital....
An interesting statistic regarding project scale:
The USA currently has enough battery storage to keep the electricity grid going for just 20 seconds. There are plans to increase this capacity by 10,000% over the next few years. This will keep the grid going for up to 1 hour in theory, and probably 20 minutes in practice.
There's much, much more to come from IES.
Certainly have!
It's rare to get a development stage pharmaceutical company awash with cash, they've not needed to raise cash from the markets for five years. In fact, they've been using spare cash to buy back shares for the last year.
Everything now hinges on FDA approval of KarXT. Obviously, Royalty Pharma are confident that it will get it.
Good find Smartpunter. The really interesting thing is that the article was written a year ago. Since then, Thacker Pass has had the go-ahead and is under construction, and the portfolio has been rejigged away from gold. Even at that stage, the author of the analysis was so impressed with the company that he bought shares in it after doing the analysis.
Says it all really.
Good to see all the directors with substantial skin in the game.
Thanks Mullins, makes sense now.
The market seems to be pricing in an appeal win for Bacanora.
It's the only explanation for the total lack of SP movement in the run-up to the verdict, unless there's something else going on. Very, very strange.
Well done bull, you've timed your T20 buy and sell really well.
We all have different strategies to make money, that's what makes a market. It's good to see someone's strategy succeeding so spectacularly.
The way the price is moving, you might get another opportunity sooner than you thought. Don't forget to tell your friends, the more liquidity here the better.
GLA.
A positive market reaction to the results of the Phase 1 trial to demonstrate oral bioavailability of CBD products using Glyph capsule technology. The trial demonstrated that the technology can be used to deliver a wide range of drugs to the lymphatic system without causing liver damage.
The possibilities of this technology are enormous.
This is the link to the interview:
https://www.energy-storage.news/ira-will-be-of-huge-value-to-us-flow-battery-maker-invinity-at-re-2022/
I found the concept of hybrid battery installations partucularly interesting. A site could have a mixture of high power short term batteries for immediate use, medium term batteries for overnight use and base load batteries for storing any excess power. VRFB is perfect for the overnight requirement.